

In the Claims:

Sub D1
C1

1. (Twice amended) A composition comprising a monoclonal antibody [specifically bound to a RET antigen on] and a cell selected from the group consisting of a multipotent neuronal progenitor (proNP) cell, a nonneuronal progenitor (NNP) cell and a committed neuronal progenitor (NP) cell, wherein said monoclonal antibody is specifically bound to all of part of the RET protein on said cell.

Sub E2

2. (Twice Amended) The [monoclonal antibody] composition according to claim 1, wherein said [RET antigen] protein consists essentially of the extracellular domain of RET.

Sub D2

4. (Twice Amended) A method for the enrichment of neural progenitor cells, said method comprising:

- a) combining a mixed population of cells comprising neural-crest derived cells comprising neural progenitor cells with [a reagent] an antibody that specifically binds to [a] all of part of the RET protein [antigen]; and
- b) selecting for RET positive cells.

Sub E2

5. (Amended) [A] The method according to claim 4 wherein said [reagents are antibodies] antibody is selected from the group consisting of polyclonal antibody, monoclonal antibody, antibody fragments, and single chain antibody.

6. (Amended) [A] The method according to claim 5, wherein [at least one of] said [antibodies] antibody is fluorochrome conjugated.

7. (Twice Amended) A method according to claim 6, wherein said selecting with said fluorochrome conjugated [antibodies] antibody is by flow cytometry.

Sub D3

8. (Twice Amended) A substantially pure population of neural crest derived neural progenitor cells where said cells are [selected from the group consisting of multipotent

neuronal progenitor (proNP) cells,] nonneuronal progenitor (NNP) cells [and committed neuronal progenitor (NP) cells].

Sub E5 → 12. (Amended) [A]The population according to claim 8 wherein said neural progenitor cells are bound to [a reagent]an antibody that specifically binds to RET [antigen]protein.

Sub D4
C3
Sub D1
Sub D5 13. (Amended) [A]The population according to claim 12 wherein said [reagent is a RET] antibody is selected from the group consisting of polyclonal antibody, monoclonal antibody, antibody fragments, and single chain antibody.

14. (Amended) [A]The population according to claim 13 wherein said antibody is a monoclonal antibody.

15. (Amended) A method for the enrichment of neural progenitor cells, said method comprising:

- a) combining a mixed population of cells comprising neural-crest derived cells comprising neural progenitor cells with a monoclonal antibody that specifically binds to [a]all of part of the RET protein [antigen]; and
- b) selecting for RET positive cells.

In the Specification:

Page 24, Table 2, third column from left, delete "38.5%" and insert --36.5%--.

Page 30, Table 3, delete the columns and data added by the Amendment filed ✓

July 29, 1998.

Page 30, Table 3, third column from the left, delete "8%?" and insert --6%--! ✓

Page 30, Table 3, rightmost column, delete "NN" and insert --NNP--. ✓

Page 30, Table 3, rightmost column, after "57" insert --%--.

Page 30, Table 3, legend, delete "fibernectin" and insert --fibronectin--! ✓